The U.S. Department of Health and Human Services announced on Oct. 28 that it will not take enforcement action against licensed pharmacists who dispense certain unapproved peptides to consumers. The policy shields state-licensed pharmacies, federal facilities, and licensed physicians who compound drug products using specific peptide bulk drug substances.
Federal Policy Shifts Course on Unapproved Compounded Peptides
Peptides are short chains of amino acids that individuals inject into their bodies for various health and wellness goals. The U.S. Food and Drug Administration essentially banned these substances in 2023 due to safety concerns.
The landscape shifted following an FDA committee meeting held in July to review scientific evidence and evaluate whether pharmacies should be permitted to dispense these items without scientific review. That committee, composed of new appointees who consulted with or were employed by companies interested in promoting or dispensing peptides, recommended allowing specialty pharmacies to distribute six specific compounds despite warnings from FDA staff.
Following those hearings, HHS determined that significant interest warranted action to expand patient access. The formal agency notice, signed by HHS Secretary Robert F. Kennedy Jr., outlines the new enforcement discretion framework. According to the policy, the administration aims to advance patient choice and freedom while appropriately protecting patient safety.
Exempt Compounds and Market Reactions
The substances listed for permitted compounding under Appendix A comprise BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
Market analysts project the total commercial value of the peptide sector could reach $3.3 billion. Following the Oct. 28 announcement, stock for Hims & Hers surged 5%.
Proponents of the policy argue that establishing a legal pathway eliminates unsafe gray and black markets. Lee Rosebush, chair of the American Academy of Peptide Medicine, stated that the move represents a vital step toward restoring safe patient access through legitimate, physician-supervised care.
Public Health Concerns and Industry Warnings
Public health professionals have expressed alarm over the decision to permit compounding absent scientific evidence. Critics note that consumers risk serving as test subjects for experimental medications lacking standard regulatory backing.
Fred Mills, chief policy officer for Americans for Safe and Effective Medicines, argued that American consumers should not be treated like guinea pigs. During the July public hearings, Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University Medical Center, warned that the targeted substances remain untested and poorly characterized, pointing to an incident where two women required emergency treatment after receiving peptides at a Las Vegas festival.
Compounding pharmacies face mounting operational pressure as telehealth networks market the newly permitted peptides for prices ranging from $199 to $249 per month. Critics have expressed concern that pharmacies rushing into this space will move to make a dollar faster rather than make sure they meet every requirement, from ingredient sourcing and facilities to staff training and sterility testing.
